Poster: IBCL-081 MAGNIFY Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis

Autor: Lansigan, Frederick 1, Andorsky, David Jacob 2, Coleman, Morton 3, Yacoub, Abdulraheem 4, Melear, Jason M. 5, Fanning, Suzanne R. 6, Kolibaba, Kathryn S. 7, Reynolds, Chris 8, Nowakowski, Grzegorz S. 9, Gharibo, Mecide 10, Ahn, Jung Ryun 10, Li, Ju 10, Rummel, Mathias J. 11, Sharman, Jeff P. 12
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S172-S172
Databáze: ScienceDirect
Externí odkaz: